{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:02:35Z","timestamp":1776848555996,"version":"3.51.2"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ahj.2021.02.001","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T12:35:42Z","timestamp":1612874142000},"page":"12-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study"],"prefix":"10.1016","volume":"235","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1073-3721","authenticated-orcid":false,"given":"Warren H.","family":"Capell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliot S.","family":"Barnathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex C.","family":"Spyropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Bull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Lipardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Sugarmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunyoung","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaya Prakash","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Hiatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc P.","family":"Bonaca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2021.02.001_bib0001","first-page":"1775","article-title":"Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy","volume":"323","author":"Onder","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2021.02.001_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2020.100618","article-title":"COVID-19 and multiorgan response","volume":"45","author":"Zaim","year":"2020","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.ahj.2021.02.001_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102433","article-title":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak","volume":"109","author":"Rothan","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ahj.2021.02.001_bib0004","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2021.02.001_bib0005","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/jth.14830","article-title":"Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia","volume":"18","author":"Cui","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2021.02.001_bib0006","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.ahj.2021.02.001_bib0007","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.13372","article-title":"Thrombosis in hospitalized patients with COVID-19 in a New York City Health System","author":"Bilaloglu","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2021.02.001_bib0008","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2020.04.024","article-title":"Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy","volume":"191","author":"Lodigiani","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.ahj.2021.02.001_bib0009","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2021.02.001_bib0010","article-title":"Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality","author":"Billett","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2021.02.001_bib0011","unstructured":"Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients. Available from: https:\/\/www.nih.gov\/news-events\/news-releases\/full-dose-blood-thinners-decreased-need-life-support-improved-outcome-hospitalized-covid-19-patients; Accessed 26 January, 2021."},{"key":"10.1016\/j.ahj.2021.02.001_bib0012","unstructured":"NIH ACTIV Trial of blood thinners pauses enrollment of critically ill COVID-19 patients. Available from: https:\/\/www.nih.gov\/news-events\/news-releases\/nih-activ-trial-blood-thinners-pauses-enrollment-critically-ill-covid-19-patients; Accessed 26 January, 2021."},{"key":"10.1016\/j.ahj.2021.02.001_bib0013","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/jth.14929","article-title":"Scientific and Standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19","volume":"18","author":"Spyropoulos","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2021.02.001_bib0014","doi-asserted-by":"crossref","unstructured":"World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/clinical-management-of-novel-cov.pdf; Accessed 26 January, 2021.","DOI":"10.15557\/PiMR.2020.0003"},{"key":"10.1016\/j.ahj.2021.02.001_bib0015","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1055\/s-0040-1710019","article-title":"Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines","volume":"120","author":"Zhai","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2021.02.001_bib0016","article-title":"Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: position paper from VAS-European Independent Foundation in Angiology\/Vascular Medicine","author":"Gerotziafas","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2021.02.001_bib0017","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","article-title":"COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC State-of-the-Art Review","volume":"75","author":"Bikdeli","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.02.001_bib0018","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.thromres.2020.05.031","article-title":"COVID-19 and hypercoagulability in the outpatient setting","volume":"192","author":"Emert","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.ahj.2021.02.001_bib0019","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.thromres.2020.08.032","article-title":"Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19","volume":"196","author":"Naymagon","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.ahj.2021.02.001_bib0020","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.02.001_bib0021","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19","volume":"383","author":"Ackermann","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.02.001_bib0022","doi-asserted-by":"crossref","first-page":"350","DOI":"10.7326\/M20-2566","article-title":"Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series","volume":"173","author":"Lax","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2021.02.001_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.carpath.2020.107263","article-title":"Analysis of cardiopulmonary findings in COVID-19 fatalities: High incidence of pulmonary artery thrombi and acute suppurative bronchopneumonia","volume":"49","author":"Grosse","year":"2020","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.ahj.2021.02.001_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2020.07.023","article-title":"A review of the main histopathological findings in the Coronavirus Disease 2019 (COVID-19)","author":"Vasquez-Bonilla","year":"2020","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ahj.2021.02.001_bib0025","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M20-2003","article-title":"Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study","volume":"173","author":"Wichmann","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ahj.2021.02.001_bib0026","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S2213-2600(20)30243-5","article-title":"Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans","volume":"8","author":"Fox","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ahj.2021.02.001_bib0027","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-8-3","article-title":"Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL protocol","volume":"9","author":"Iturbe-Hernandez","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.ahj.2021.02.001_bib0028","article-title":"Does chronic treatment with oral anticoagulants ameliorate the clinical course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in coronavirus disease 2019 (COVID-19)","author":"Harenberg","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ahj.2021.02.001_bib0029","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2021.02.001_bib0030","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.02.001_bib0031","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.02.001_bib0032","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1111096","article-title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","volume":"368","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.02.001_bib0033","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without Aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.02.001_bib0034","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMoa1805090","article-title":"Rivaroxaban for thromboprophylaxis after hospitalization for medical illness","volume":"379","author":"Spyropoulos","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.02.001_bib0035","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.02.001_bib0036","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/jth.14146","article-title":"Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study","volume":"16","author":"Cohoon","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2021.02.001_bib0037","article-title":"The potential role of coagulation factor Xa in the pathophysiology of COVID-19: a role for anticoagulants as multimodal therapeutic agents","author":"Frydman","year":"2020","journal-title":"Thromb Haemost Open"},{"key":"10.1016\/j.ahj.2021.02.001_bib0038","doi-asserted-by":"crossref","DOI":"10.1177\/1076029619886022","article-title":"Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study","volume":"25","author":"Spyropoulos","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.ahj.2021.02.001_bib0039","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1055\/s-0039-1701009","article-title":"Thromboprophylaxis with rivaroxaban in acutely ill medical patients with renal impairment: insights from the MAGELLAN and MARINER trials","volume":"120","author":"Weitz","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2021.02.001_bib0040","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1160\/TH07-12-0714","article-title":"Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement","volume":"100","author":"Mueck","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ahj.2021.02.001_bib0041","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1161\/CIRCULATIONAHA.116.025427","article-title":"Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)","volume":"135","author":"Gibson","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2021.02.001_bib0042","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.jacc.2020.04.071","article-title":"Post-discharge prophylaxis with rivaroxaban reduces fatal and major thromboembolic events in medically ill patients","volume":"75","author":"Spyropoulos","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.02.001_bib0043","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2021.02.001_bib0044","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1093\/ajhp\/zxaa286","article-title":"Development of pulmonary embolism in a nonhospitalized patient with COVID-19 who did not receive venous thromboembolism prophylaxis","volume":"77","author":"Uppuluri","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ahj.2021.02.001_bib0045","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.thromres.2020.06.032","article-title":"Venous thromboembolism and coronavirus disease 2019 in an ambulatory care setting - A report of 4 cases","volume":"194","author":"Overstad","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.ahj.2021.02.001_bib0046","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2020.08.070","article-title":"Registry of arterial and venous thromboembolic complications in patients with COVID-19","volume":"76","author":"Piazza","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2021.02.001_bib0047","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.59209","article-title":"Inference from longitudinal laboratory tests characterizes temporal evolution of COVID-19-associated coagulopathy (CAC)","volume":"9","author":"Pawlowski","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.ahj.2021.02.001_bib0048","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/2168479012469947","article-title":"Benchmarking the Study Initiation Process","volume":"47","author":"Lamberti","year":"2013","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.ahj.2021.02.001_bib0049","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1001\/jama.2012.14841","article-title":"Transforming clinical trials in cardiovascular disease: mission critical for health and economic well-being","volume":"308","author":"Antman","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2021.02.001_bib0050","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/eurheartj\/ehv213","article-title":"Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology","volume":"37","author":"Jackson","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2021.02.001_bib0051","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1186\/s13063-020-04678-4","article-title":"Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial","volume":"21","author":"Barco","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.ahj.2021.02.001_bib0052","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1111\/bjh.16968","article-title":"COVID-19 mortality in patients on anticoagulants and antiplatelet agents","volume":"190","author":"Sivaloganathan","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ahj.2021.02.001_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104965","article-title":"Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study","volume":"159","author":"Russo","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ahj.2021.02.001_bib0054","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1016\/S2352-3026(20)30145-9","article-title":"Coagulation abnormalities and thrombosis in patients with COVID-19","volume":"7","author":"Levi","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ahj.2021.02.001_bib0055","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1111\/bjh.16850","article-title":"COVID-19-associated immune thrombocytopenia","volume":"190","author":"Bomhof","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ahj.2021.02.001_bib0056","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1056\/NEJMc2010472","article-title":"Immune thrombocytopenic purpura in a patient with Covid-19","volume":"382","author":"Zulfiqar","year":"2020","journal-title":"N Engl J Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321000338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870321000338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:06:27Z","timestamp":1757570787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870321000338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":56,"alternative-id":["S0002870321000338"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2021.02.001","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2021.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}